NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $5.41 +0.09 (+1.69%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.38 -0.04 (-0.65%) As of 10/3/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Abeona Therapeutics Stock (NASDAQ:ABEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$5.31▼$5.4950-Day Range$5.28▼$7.2352-Week Range$3.93▼$7.54Volume1.04 million shsAverage Volume1.05 million shsMarket Capitalization$277.42 millionP/E Ratio7.73Dividend YieldN/APrice Target$19.50Consensus RatingModerate Buy Company Overview Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need. The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa. These candidates have advanced through early‐stage trials, offering initial proof of concept in delivering corrective genetic material to affected tissues. Abeona is also exploring innovative oncology cell therapy approaches that apply its gene delivery expertise to tumor targeting. Abeona supports its pipeline with cGMP manufacturing facilities in Cleveland and Cambridge, complemented by a research presence in the Texas Medical Center to scale vector production and process development. The company has forged strategic collaborations to streamline clinical supply and broaden patient access, reflecting its commitment to advancing transformative medicines globally. Under the guidance of its executive leadership, Abeona continues to engage with regulatory authorities and expand clinical trial initiatives across North America and Europe.AI Generated. May Contain Errors. Read More Abeona Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreABEO MarketRank™: Abeona Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 119th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingAbeona Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialAbeona Therapeutics has a consensus price target of $19.50, representing about 260.4% upside from its current price of $5.41.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Abeona Therapeutics are expected to decrease in the coming year, from ($1.16) to ($1.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is 7.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 284.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is 7.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 78.05.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Abeona Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.14% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Abeona Therapeutics has recently decreased by 3.32%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.03 Percentage of Shares Shorted19.14% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Abeona Therapeutics has recently decreased by 3.32%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.20 News SentimentAbeona Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Abeona Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,221,990.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABEO Stock News HeadlinesJoseph Walter Vazzano Sells 9,035 Shares of Abeona Therapeutics (NASDAQ:ABEO) StockOctober 2 at 5:51 AM | insidertrades.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1 at 7:30 AM | globenewswire.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.October 4 at 2:00 AM | Porter & Company (Ad)Should You Invest in Abeona Therapeutics (ABEO)?September 8, 2025 | insidermonkey.comAbeona Therapeutics Inc. Stock (ABEO) Opinions on Upcoming Revenue InitiationSeptember 5, 2025 | quiverquant.comQAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comAbeona Therapeutics® Announces Participation in Upcoming Investor ConferencesAugust 29, 2025 | globenewswire.comAbeona Therapeutics Inc. (NASDAQ:ABEO) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | msn.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.57 on January 1st, 2025. Since then, ABEO stock has decreased by 2.9% and is now trading at $5.41. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc. (NASDAQ:ABEO) released its quarterly earnings results on Thursday, August, 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, beating the consensus estimate of ($0.39) by $2.10. The biopharmaceutical company had revenue of $0.40 million for the quarter, compared to analysts' expectations of $21.71 million. Read the conference call transcript. When did Abeona Therapeutics' stock split? Abeona Therapeutics shares reverse split before market open on Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), CymaBay Therapeutics (CBAY) and GE Aerospace (GE). Company Calendar Last Earnings8/14/2025Today10/04/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101Employees90Year Founded2013Price Target and Rating Average Price Target for Abeona Therapeutics$19.50 High Price Target$20.00 Low Price Target$18.00 Potential Upside/Downside+260.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio7.73 Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.73 million Net MarginsN/A Pretax Margin18,188.50% Return on Equity89.05% Return on Assets45.64% Debt Debt-to-Equity Ratio0.09 Current Ratio6.73 Quick Ratio6.65 Sales & Book Value Annual Sales$400 thousand Price / Sales693.55 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book5.36Miscellaneous Outstanding Shares51,279,000Free Float47,741,000Market Cap$277.42 million OptionableOptionable Beta1.42 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ABEO) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.